These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26922636)

  • 1. A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.
    Khasnavis T; Reiner G; Sommerfeld B; Nyhan WL; Chipkin R; Jinnah HA
    Mol Genet Metab; 2016 Apr; 117(4):401-6. PubMed ID: 26922636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.
    Khasnavis T; Torres RJ; Sommerfeld B; Puig JG; Chipkin R; Jinnah HA
    Mol Genet Metab; 2016 Jul; 118(3):160-166. PubMed ID: 27179999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards rational drug treatment of Lesch-Nyhan disease.
    Seifert R
    Mol Genet Metab; 2016 Jul; 118(3):145-146. PubMed ID: 27216368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans.
    Haney M; Ward AS; Foltin RW; Fischman MW
    Psychopharmacology (Berl); 2001 Jun; 155(4):330-7. PubMed ID: 11441422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecopipam as a pharmacologic treatment of stuttering.
    Maguire GA; LaSalle L; Hoffmeyer D; Nelson M; Lochhead JD; Davis K; Burris A; Yaruss JS
    Ann Clin Psychiatry; 2019 Aug; 31(3):164-168. PubMed ID: 31369655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine.
    Nann-Vernotica E; Donny EC; Bigelow GE; Walsh SL
    Psychopharmacology (Berl); 2001 Jun; 155(4):338-47. PubMed ID: 11441423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study.
    Gilbert DL; Murphy TK; Jankovic J; Budman CL; Black KJ; Kurlan RM; Coffman KA; McCracken JT; Juncos J; Grant JE; Chipkin RE
    Mov Disord; 2018 Aug; 33(8):1272-1280. PubMed ID: 30192018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Lesch-Nyhan disease with S-adenosylmethionine: experience with five young Malaysians, including a girl.
    Chen BC; Balasubramaniam S; McGown IN; O'Neill JP; Chng GS; Keng WT; Ngu LH; Duley JA
    Brain Dev; 2014 Aug; 36(7):593-600. PubMed ID: 24055166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory cross-over, trial of augmented RLS with the dopamine receptor 1/5 antagonist ecopipam D1/D5 antagonist ecopipam for augmented RLS.
    Ondo WG; Olubajo T
    Int J Neurosci; 2022 Aug; 132(8):778-782. PubMed ID: 33066723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of new forms of self-injurious behavior following total dental extraction in Lesch-Nyhan disease.
    Gisbert de la Cuadra L; Torres RJ; Beltrán LM; Sánchez A; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):524-528. PubMed ID: 27906614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behavior by influencing D1-dopamine receptor function.
    Breese GR; Criswell HE; Mueller RA
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14 Suppl():S65-80. PubMed ID: 1982973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.
    Gilbert DL; Budman CL; Singer HS; Kurlan R; Chipkin RE
    Clin Neuropharmacol; 2014; 37(1):26-30. PubMed ID: 24434529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects.
    Astrup A; Greenway FL; Ling W; Pedicone L; Lachowicz J; Strader CD; Kwan R;
    Obesity (Silver Spring); 2007 Jul; 15(7):1717-31. PubMed ID: 17636090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa is not a useful treatment for Lesch-Nyhan disease.
    Visser JE; Schretlen DJ; Bloem BR; Jinnah HA
    Mov Disord; 2011 Mar; 26(4):746-9. PubMed ID: 21506156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine, dopamine and serotonin receptors imbalance in lymphocytes of Lesch-Nyhan patients.
    García MG; Puig JG; Torres RJ
    J Inherit Metab Dis; 2012 Nov; 35(6):1129-35. PubMed ID: 22403020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal adenosine and dopamine receptor expression in lymphocytes of Lesch-Nyhan patients.
    García MG; Puig JG; Torres RJ
    Brain Behav Immun; 2009 Nov; 23(8):1125-31. PubMed ID: 19635551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.
    Karle J; Clemmesen L; Hansen L; Andersen M; Andersen J; Fensbo C; Sloth-Nielsen M; Skrumsager BK; Lublin H; Gerlach J
    Psychopharmacology (Berl); 1995 Oct; 121(3):328-9. PubMed ID: 8584614
    [No Abstract]   [Full Text] [Related]  

  • 18. Behavioral aspects of Lesch-Nyhan disease and its variants.
    Schretlen DJ; Ward J; Meyer SM; Yun J; Puig JG; Nyhan WL; Jinnah HA; Harris JC
    Dev Med Child Neurol; 2005 Oct; 47(10):673-7. PubMed ID: 16174310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166).
    Chausmer AL; Smith BJ; Kelly RY; Griffiths RR
    Behav Pharmacol; 2003 Mar; 14(2):111-20. PubMed ID: 12658071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen.
    Pozzi M; Piccinini L; Gallo M; Motta F; Radice S; Clementi E
    Orphanet J Rare Dis; 2014 Dec; 9():208. PubMed ID: 25497359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.